Table 1.
Parameter | pSS | Controls |
Characteristics | ||
n | 76 | 28 |
Sex (male, female) | 3, 73 | 6, 22 |
Agea (years) | 49.2 ± 13.8 | 51 ± 11.4 |
Disease durationa (years) | 7.2 ± 4.1 | - |
Clinical findings | ||
Conjunctivitis | 26 (34) | None |
Parotid swelling | 22 (28) | None |
Arthralgia | 51 (67) | None |
Myalgia | 17 (22) | None |
Raynaud's phenomenon | 20 (26) | None |
Peripheral neuropathy | 11 (14) | None |
Generalized tendomyopathy | 9 (12) | None |
Skin involvement | 9 (12) | None |
Pulmonary involvement | 12 (16) | None |
Renal involvement | 10 (13) | None |
Thyroiditis | 12 (16) | None |
Lymphoma | 3 (4) | None |
Laboratory findings | ||
Antinuclear antibodies | 76 (100) | Negative |
RF (Waaler–Rose test) | 60 (79) | Negative |
Anti-Ro/SS-A antibodies | 69 (91) | Negative |
Anti-La/SS-B antibodies | 47 (62) | Negative |
Hypergammaglobulinemia | 57 (75) | Negative |
Leukocytopenia | 29 (38) | Negative |
Anemia | 9 (13) | Negative |
Thrombopenia | 4 (5) | Negative |
Low complement C3c | 20 (26) | Negative |
Low complement C4 | 12 (16) | Negative |
Numbers in parentheses are percentages of the total. pSS, primary Sjögren's syndrome; RF, rheumatoid factor; SS, Sjögren's syndrome. aMean ± SD.